All In MedTech

Device Trial Radar · NCT07153094

Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

47

Actual

Start

Aug 4, 2025

Primary completion

Aug 31, 2026

Study completion Jul 2031

Sponsor

Lead sponsor
Ion Beam ApplicationsNot on our public-company list
Sponsor type
Industry
First posted
Sep 3, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will enroll 47 subjects who will be be treated with the IBA PROTEUS® PLUS Proton Beam radiation Therapy (PBT) medical device. The trial aims to assess the safety and efficacy of PROTEUS® PLUS for radiation therapy to oncology patients, and to provide a clinical basis for product registration application.

Conditions

  • Solid Tumor, Adult

Interventions

  • Proton Beam Therapy (PBT)Device

    PROTEUS® PLUS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Short term efficacy evaluationTime frame: 90 days after the treatment completion
  2. Short term safety evaluationTime frame: 90 days after the treatment completion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

    Shenzhen, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.